Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real‐life combo study

This multicentre observational study evaluated the feasibility, efficacy and toxicity of antifungal combination therapy (combo) as treatment of proven or probable invasive fungal diseases (IFDs) in patients with haematological malignancies. Between January 2005 and January 2010, 84 cases of IFDs (39 proven and 45 probable) treated with combo were collected in 20 Hematological Italian Centres, in patients who underwent chemotherapy or allogeneic haematopoietic stem cell transplantation for haematological diseases. Median age of patients was 34 years (range 1–73) and 37% had less than 18 years. Acute leukaemia was the most common underlying haematological disease (68/84; 81%). The phase of treatment was as follows: first induction in 21/84 (25%), consolidation phase in 18/84 (21%) and reinduction/salvage in 45/84 (54%). The main site of infection was lung with or without other sites. The principal fungal pathogens were as follows: Aspergillus sp. 68 cases (81%), Candida sp. six cases (8%), Zygomycetes four cases (5%) and Fusarium sp. four cases (5%). The most used combo was caspofungin+voriconazole 35/84 (42%), caspofungin + liposomal amphotericin B (L‐AmB) 20/84 (24%) and L‐AmB+voriconazole 15/84 (18%). The median duration of combo was 19 days (range 3–180). The overall response rate (ORR) was 73% (61/84 responders) without significant differences between the combo regimens. The most important factor that significantly influenced the response was granulocyte (PMN) recovery (P 0.009). Only one patient discontinued therapy (voriconazole‐related neurotoxicity) and 22% experienced mild and reversible adverse events (hypokalaemia, ALT/AST increase and creatinine increase). The IFDs‐attributable mortality was 17%. This study indicates that combo was both well tolerated and effective in haematological patients. The most used combo regimens were caspofungin + voriconazole (ORR 80%) and caspofungin + L‐AmB (ORR 70%). The ORR was 73% and the mortality IFD related was 17%. PMN recovery during combo predicts a favourable outcome. Clinical Trials Registration: NCT00906633.

[1]  J. Wingard,et al.  Combination Antifungal Therapy for Invasive Aspergillosis , 2015, Annals of Internal Medicine.

[2]  D. Kontoyiannis,et al.  Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis , 2014, Mycoses.

[3]  Ronald N. Jones,et al.  Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance , 2013, Journal of Clinical Microbiology.

[4]  L. Pagano,et al.  Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries , 2013, Haematologica.

[5]  M. Sanz,et al.  Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination , 2012, Mediterranean journal of hematology and infectious diseases.

[6]  A. Thiébaut,et al.  European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update , 2011, Bone Marrow Transplantation.

[7]  C. Cordonnier,et al.  Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study , 2011, Haematologica.

[8]  N. Kröger,et al.  Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients , 2011, Mycoses.

[9]  I. Raad,et al.  Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? , 2010, Cancer.

[10]  C. Romano,et al.  Zygomycosis in Italy: A Survey of FIMUA-ECMM (Federazione Italiana Di Micopatologia Umana ed Animale and European Confederation of Medical Mycology) , 2009, Journal of chemotherapy.

[11]  Nilo A. Avila,et al.  Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose- Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis , 2009, Antimicrobial Agents and Chemotherapy.

[12]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  D. Denning,et al.  Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[14]  E. Anaissie,et al.  Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  C. Junghanss,et al.  Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) , 2009, Annals of Hematology.

[16]  J. Perfect,et al.  Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Fiegl,et al.  A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients , 2008, Annals of Hematology.

[18]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  B. Spellberg,et al.  Combination Echinocandin-Polyene Treatment of Murine Mucormycosis , 2008, Antimicrobial Agents and Chemotherapy.

[20]  S. de Botton,et al.  Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies , 2007, Cancer.

[21]  J. Perfect,et al.  Combination antifungal therapy: what can and should we expect? , 2007, Bone Marrow Transplantation.

[22]  A. Glasmacher,et al.  Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis , 2006, Cancer.

[23]  Russell E. Lewis,et al.  Decision Making in Antifungal Monotherapy versus Combination Therapy , 2006, Pharmacotherapy.

[24]  T. Patterson,et al.  Sequential or Combination Antifungal Therapy with Voriconazole and Liposomal Amphotericin B in a Guinea Pig Model of Invasive Aspergillosis , 2006, Antimicrobial Agents and Chemotherapy.

[25]  C. McCulloch,et al.  Impact of a Piperacillin‐Tazobactam Shortage on Antimicrobial Prescribing and the Rate of Vancomycin‐Resistant Enterococci and Clostridium difficile Infections , 2006, Pharmacotherapy.

[26]  Steve A. Hernandez,et al.  Caspofungin and Liposomal Amphotericin B Therapy of Experimental Murine Scedosporiosis , 2005, Antimicrobial Agents and Chemotherapy.

[27]  D. MacCallum,et al.  Efficacy of Caspofungin and Voriconazole Combinations in Experimental Aspergillosis , 2005, Antimicrobial Agents and Chemotherapy.

[28]  D. Kontoyiannis,et al.  Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis , 2005, Cancer.

[29]  J. Powers.  Considerations in clinical trials of combination antifungal therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  Russell E. Lewis,et al.  Toward more effective antifungal therapy: the prospects of combination therapy , 2004, British journal of haematology.

[31]  Russell E. Lewis,et al.  Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies , 2003, Cancer.

[32]  T. Walsh,et al.  Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. , 2003, The Journal of infectious diseases.

[33]  G. Alangaden,et al.  Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. , 2003, The Journal of antimicrobial chemotherapy.

[34]  K. Sepkowitz,et al.  Refractory Aspergillus pneumonia in patients with acute leukemia , 2003, Cancer.

[35]  J. Rex,et al.  In Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium spp , 2002, Antimicrobial Agents and Chemotherapy.

[36]  D. Kontoyiannis,et al.  Rationale for Combination Antifungal Therapy , 2001, Pharmacotherapy.

[37]  Qinying Zhao,et al.  Influence of Coadministration of Fluoxetine on Cisapride Pharmacokinetics and QTc Intervals in Healthy Volunteers , 2001, Pharmacotherapy.

[38]  D. Alling,et al.  A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. , 1979, The New England journal of medicine.

[39]  D. Lalloo,et al.  Combination antifungal therapy for cryptococcal meningitis. , 2013, The New England journal of medicine.

[40]  S. Kravchenko,et al.  INVASIVE ASPERGILLOSIS IN PATIENTS WITH ACUTE LEUKEMIA , 2013 .

[41]  G. Maschmeyer,et al.  Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. , 2007, Drugs.

[42]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  H. Bloom,et al.  Hematologic Malignancies , 1986, UICC Current Treatment of Cancer.

[44]  A RANDOMISED , 2022 .